Regentis Biomaterials is a privately-owned biotechnology startup based in Or Akiva, Israel. The company specializes in the development and commercialization of a unique hydrogel platform designed for tissue repair. Their primary focus is on orthopedic treatments, where they use resorbable hydrogel implants to regenerate damaged or diseased tissue.

The company's business model revolves around the development, manufacturing, and sale of these innovative hydrogel products. Their main product, GelrinC, is manufactured under strict international safety, quality, and biocompatibility standards, including Good Manufacturing Practice (GMP) and ISO 13485. This ensures the product's safety and effectiveness in tissue repair therapies.

Regentis Biomaterials operates in the global biotechnology market, specifically in the orthopedic treatments segment. Their clients are primarily healthcare providers and patients who require orthopedic treatments. The company generates revenue through the sale of their hydrogel products to these healthcare providers.

The company has attracted investments from several entities, including Medica Venture Partners, SCPVitalife, Royal DSM through its venturing subsidiary, the Crossroad Fund, Haisco Pharmaceutical Group Co. Ltd., Technion Investment Opportunities Fund, ProSeed, and Shalom Equity Fund. This indicates a strong belief in the potential of the company's innovative tissue repair solutions.

In summary, Regentis Biomaterials is a promising biotech startup with a unique product offering in the orthopedic treatments market. Their vision is to develop effective tissue repair therapies that not only improve patients' quality of life but also shorten their recovery times.

Keywords: Regentis Biomaterials, Hydrogel Platform, Tissue Repair, Orthopedic Treatments, Resorbable Hydrogel Implants, Biotechnology, GelrinC, Healthcare Providers, Tissue Regeneration, Biocompatibility Standards.